The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report
Campbell, E.J, Bonomo, Y, Collins, L, norman, A, O’Neill, H, Streitberg, A, Galloway, K, Kyoong, A, Perkins, A, Pastor, A, Lawrence, A.j.
Clinical Case Reports - 2024
Effective medications for the treatment of alcohol use disorder are limited. This is partially due to the heterogenous nature of the symptomatology associated with alcohol use disorder and the abundance of presenting comorbidities. One common, and often overlooked, symptom that occurs during withdrawal of alcohol use is sleep disruption. Here, we report a case study of a participant with comorbid alcohol use disorder and insomnia. This participant was treated with a dual orexin receptor antagonist, suvorexant (Belsomra®), currently approved to treat insomnia. We demonstrate improvements in alcohol cravings, physical and psychological health, and sleep outcomes with treatment. These data support abundant preclinical and emerging clinical data in this space. The findings from this case report highlight the potential for suvorexant to treat comorbid alcohol use disorder and insomnia with fully powered, randomized controlled trials moving forward.